News & Media > BHIVA responds to JCVI recommendation on HPV vaccination for MSM

BHIVA responds to JCVI recommendation on HPV vaccination for MSM

Wednesday 12 November 2014

British HIV Association (BHIVA) response to Joint Committee on Vaccination and Immunisation (JCVI) advice to the Department of Health about a targeted programme of human papillomavirus (HPV) vaccination via genito-urinary medicine (GUM) clinics for men who have sex with men (MSM).

Welcoming today's JCVI advice, BHIVA Chair, Dr David Asboe, said: "Offering HPV vaccination to MSM attending GUM clinics is a simple, low-cost clinical intervention that will undoubtedly save lives. HPV disease - particularly anal cancer – disproportionally affects MSM, especially those who are HIV positive. We look forward to contributing fully to the JCVI's proposed stakeholder consultation."

For further information or comment, please contact Curium Communications:
Jon Cope: 07867 508212
[email protected]

Founded in 1995, BHIVA is a well-established organisation which is committed to providing excellence in the care of those living with and affected by HIV. It acts as a national advisory body to professions and other organisations on all aspects of HIV care. BHIVA also provides a national platform for HIV care and contributes representatives for international, national and local committees dealing with HIV care. In addition, BHIVA works to promote undergraduate, postgraduate and continuing medical education within HIV care. Visit for more information about BHIVA, and follow us on Twitter @BritishHIVAssoc